Pulmonary Hypertension: Key market research findings
- Increased focus towards combination therapies
- Introduction of new disease-modifying drugs
Technavio has added a new market research report on the global pulmonary hypertension market to its pulmonary disease portfolio. Technavio’s market research analysts estimate the pulmonary hypertension market to grow at a CAGR of around 3% between 2015 and 2019. The Americas dominate the market, and is expected to occupy more than 52% of the total market share by 2019. This region’s high market share can be attributed to factors such as the increasing focus on combination therapies and the recent increase in the number of geriatric population in this region.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for growth, as well as the segments with the maximum growth potential.
“There has been a considerable shift towards combination therapies for hypertension treatment. Combination therapy with separate agents or a fixed-dose combination pill lowers blood pressure at a faster pace, help in obtaining target blood pressure, and decrease adverse effects. Several combinations such as ERAs with prostanoids, phosphodiesterase inhibitors (PDEs) with ERAs, and prostanoids with PDEs are used in improving pulmonary hemodynamics. Of late, the increased use of fixed-dose combinations are fuelling this market growth,” says Imran Mushtaq, Lead Analyst, Healthcare, Technavio Research.
Vendors are focusing towards the development of novel pipeline molecules with disease-modifying characteristics. These novel agents will target the receptors that propagate the disorder. Manufacturers are expected to launch new drugs such as Uptravi and Trevyent with better safety, efficacy, and disease-modifying features during the forecast period. Currently, Actelion Pharmaceuticals dominates the market due to its drug, Tracleer, which has made significant sales in the recent years.
The leading vendors in the global pulmonary hypertension market are Actelion, Bayer, GlaxoSmithKline, and United Therapeutics. This market is highly competitive and is dominated by the presence of large vendors like Actelion, Bayer, GlaxoSmithKline, and United Therapeutics. The acceptance and launch of novel formulations is expected to propel the revenue generated by the vendors in this market.
A more detailed analysis is available in the Technavio report, Pulmonary Hypertension – Global Market Research 2015-2019.
We can customize reports by other regions and specific segments upon request.
Other Related Reports:
